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Abstract—While myalgic encephalomyelitis/chronic fatigue
syndrome (ME/CFS) is relatively new and poorly understood, a
recent upsurge in research has identified the disease’s core
symptoms, including post-exertional malaise and orthostatic
intolerance. The FDA has yet to approve any treatments for
ME/CFS, partially due to a lack of validated efficacy endpoints.
The central focus of this research is to develop ME/CFS
efficacy endpoints using a non-invasive, inertial measurementbased approach. Accessible endpoints will provide a way to
properly evaluate potential treatments for ME/CFS. Using a
Kalman filter, inertial measurement unit (IMU) data can be
converted to optimized leg angle estimates. These angle estimates
can then be converted to personalized daily measurements of
upright activity, referred to as uptime.
In a six-day, case-control study conducted by the Bateman
Horne Center, uptime was measured for 15 subjects (five controls,
five moderate-level ME/CFS, and five severe-level ME/CFS).
Analysis of these uptime scores indicated that each group spends
different proportions of their days upright and active. This result
shows that uptime can accurately determine disease severity and is,
therefore, a reliable endpoint for evaluating ME/CFS treatment
efficacy.

NOMENCLATURE
𝜙

Roll, angle relative to a global x-axis

𝜃

Pitch, angle relative to a global z-axis

𝜓

Yaw, angle relative to a global y-axis

𝑎𝑥

Acceleration along the x-axis

𝑎𝑦

Acceleration along the y-axis

𝑎𝑧

Acceleration along the z-axis

𝑝

Body fixed rotation rate about the x-axis

𝑞

Body fixed rotation rate about the y-axis

𝑟

Body fixed rotation rate about the z-axis

𝜃𝑐

Critical angle, measured from vertical

I.

INTRODUCTION

More than two million Americans suffer from myalgic
encephalomyelitis/chronic fatigue syndrome (ME/CFS), with an
annual cost of $24 billion [1][2]. While our understanding of the
etiology of ME/CFS is currently incomplete, studies have shown
that the disease commonly occurs following viral infection and
other acutely stressful events, impacting women more frequently
than men at a rate of 6:1 [3]. A recent upsurge in ME/CFS
research has led to an understanding of the disease’s core
symptoms: (1) fatigue as a response to physical exertion, (2)
post-exertional malaise (PEM), (3) unrefreshing sleep, (4)
cognitive impairment, and (5) orthostatic intolerance (OI) [4].
While the scientific community’s understanding of ME/CFS is
continuously improving, no cure has been discovered. Patients
often suffer from ME/CFS for years, and sometimes even until
death [5].
PEM causes individuals with ME/CFS to become
disproportionately fatigued following mental or physical
exertion. It is regarded as the distinctive symptom of ME/CFS
[6]. As a result of PEM, individuals with ME/CFS can have
difficulty performing mundane tasks such as routine cleaning,
grocery shopping, and even showering.
OI refers to the onset of symptoms that occur when standing
upright; these symptoms can be alleviated by reclining. While
the exact cause of OI remains unknown, Dr. van Campen’s
research suggests that significantly lower blood volume is
common among adults with ME/CFS who experience OI [7].
Sub-normal blood volume is likely the cause of the circulationrelated issues many ME/CFS patients endure, such as dizziness,
headaches, weakness, and nausea. These are the most common
symptoms of OI, all of which occur as a result of prolonged
upright posture.
The FDA has yet to approve any treatments—physical or
pharmaceutical—for ME/CFS. To some extent, this lack of
FDA-approved treatments is due to a lack of validated efficacy
endpoints [4]. Efficacy endpoints are used in clinical trials to
reliably monitor the improvement of subjects as a result of a
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prescribed treatment. In recent years, researchers have developed
some ME/CFS efficacy endpoints using blood tests [8] and other
invasive methods [9]. The central focus of this research is to
develop efficacy endpoints using a completely non-invasive,
inertial measurement-based approach. More accessible efficacy
endpoints will provide a way to properly evaluate potential
treatments for ME/CFS, especially if these endpoints correspond
to the disease’s core symptoms.
Researchers at the Bateman Horne Center (BHC) in Salt
Lake City, Utah recently discovered an endpoint that shows
promise as a reliable assessment of functional impairment
among patients with ME/CFS. In studies conducted by the BHC,
subjects were asked to fill out questionnaires, identifying how
much time they spent upright during the previous 24 hours. The
BHC refers to this measurement of uprightness as hours of
upright activity (HUA).
Due to its strong correlation with PEM, HUA is a simple
way to gauge disease severity among individuals with ME/CFS
(transcript in progress). While HUA is a valuable efficacy
endpoint, its deficiencies are significant. The primary weakness
of HUA is the inaccuracy of its current data collection method—
questionnaire [10]; it is unreasonable to expect patients to
accurately recall the amount of time they spent in an upright
position the previous day. Another weakness of HUA is the low
resolution offered by the measurement. “Hours” of upright
activity is just that, a measurement recorded as whole integers in
units of hours. Due to the inaccuracy and low resolution of data
collected from HUA questionnaires, the only way to obtain a
measurement of upright activity with a higher level of precision
involves significant alterations to the current measurement
process.
To address HUA’s shortcomings, an improved method for
evaluating upright activity is proposed. Using an inertial
measurement unit (IMU), it is possible to continuously and
accurately measure upright activity, thus providing an effective
method to assess disease severity among individuals with
ME/CFS. By continuously measuring the uprightness of the
lower legs, we can obtain a measurement referred to as uptime.
The advantages of this approach are two-fold. The first
advantage is that healthcare providers will no longer need to rely
upon the accuracy of a patient’s memory to approximate upright
activity. The second advantage comes from increasing the
resolution of the measurement from hours—HUA—to
seconds— uptime.
The goal of our research is to validate an improved method
to assess upright activity. To formally evaluate uptime as an
efficacy endpoint for ME/CFS disease severity, this research
evaluates the results of a study wherein a healthy control group
and an experimental group of ME/CFS patients were outfitted
with Shimmers—a commercially available IMU—for six
consecutive days. During these six days, the Shimmers
continuously measured uptime. Statistical tests and other
comparisons were used to evaluate the correlation between data
collected by the Shimmer and uptime.

Our research simplifies symptom severity evaluation among
patients with ME/CFS. As a result, assessing the long-term
efficacy of treatments for patients with ME/CFS will
significantly improve the evaluation of disease severity in terms
of both ease and accuracy. These changes will enable the
development of effective treatments, thus providing a path to
recovery for individuals struggling with ME/CFS.
II.

MATERIALS AND METHODS

The chief objective of this research is to evaluate uptime to
prove its value as an efficacy endpoint for ME/CFS. We
accomplished this goal in three steps: (1) establish a method to
measure lower leg angle using an IMU, (2) verify the accuracy
of these IMU-based angle measurements, and (3) perform a casecontrol study comparing uptime between different ME/CFS and
non-ME/CFS groups.
A. Uptime Calculation – IMU Sensor Fusion
Calculating uptime is a two-step process. First, we measure
lower leg angle by filtering IMU data. Second, we evaluate this
measured angle to determine if the leg is upright. Distinguishing
leg uprightness is crucial because it relates to the HUA
questionnaire, which quantifies daily time spent in upright
postures (see Fig. 1).

Fig. 1. HUA survey—HUA-based estimates of uptime are calculated by
summing the time spent with feet on the floor.

To replace the HUA questionnaire, we chose to calculate
uptime using an IMU placed on each lower leg. Lower leg angles
allow us to accurately assess whether the feet are on the floor
(lower legs vertical) or off the floor (lower legs
reclined/horizontal) while maximizing user comfort.
The Shimmer, a commercially available IMU, was selected
for use in this research due to its small and lightweight design,
data logging capacity, ample battery life, and previous use in
related work [11][12]. Using an internal SD card, the Shimmer
can simultaneously record accelerometer, gyroscope, and
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magnetometer data for extended periods. Accurate angle
estimations can be obtained using only the accelerometer and
gyroscope.
Combining data from multiple sensors, otherwise known as
sensor fusion, has been extensively reviewed in the literature
[13]. Sensor fusion reduces measurement uncertainty by
merging data from multiple sensors. Our sensor fusion method
of choice, the Kalman filter, was used to merge the Shimmer’s
raw accelerometer and gyroscope data to determine lower leg
angle, measured from vertical.
Estimates of lower leg angle can be derived from both the
accelerometer and the gyroscope. Equations 1 and 2 show
estimates of roll (𝜙) and pitch (𝜃) calculated from accelerometer
data (𝑎𝑥 , 𝑎𝑦 , and 𝑎𝑧 ) using trigonometry.
𝜙𝐴𝑐𝑐 = tan−1 (
𝜃𝐴𝑐𝑐 = tan−1 (

𝑎𝑦

)

(1)

)

(2)

2 + 𝑎2
𝑎𝑥
𝑧

−𝑎𝑥

2 + 𝑎2
𝑎𝑦
𝑧

For our research, the critical angle was set equal to 39 degrees
from vertical. After determining each leg’s “uprightness,” our
MATLAB function calculated uptime as a percentage of the day
spent with the lower legs in an upright position.
B. IMU-Based Uptime Accuracy Confirmation
To confirm the accuracy of the filtered lower leg angles, we
performed a small study using a nine-camera VICON motion
capture system as a 100% accurate reference for comparison.
The Shimmer’s low-noise accelerometer was set to an output
range of ± 2 g, and the gyroscope was set to an output range of ±
500 deg/sec.
The VICON and Shimmer systems were then
simultaneously used to measure lower leg angles while three
subjects followed a series of postures, holding each for
approximately five seconds (Fig. 3).

Equation 3 shows how lower leg angle rates were estimated by
transforming raw gyroscope data (𝑝, 𝑞, and 𝑟) into global frame
Euler angle rates, which were subsequently integrated to form
angle estimates.
𝜙̇𝐺
𝑝
1 sin(𝜙) tan(𝜃) cos(𝜙) tan(𝜃)
cos(𝜙)
− sin(𝜙) ) (𝑞)
( 𝜃̇𝐺 ) = (0
0 sin(𝜙) / cos(𝜃) cos(𝜙) / cos(𝜃) 𝑟
𝜓̇𝐺

(3)

Both angle estimates were optimally combined using a Kalman
filter to minimize measurement noise and bias error.
A custom MATLAB function calculated uptime by
comparing the Kalman filter’s optimized lower leg angle
estimates to a critical angle. The role of the critical angle is to
mark the difference between a lower leg that is upright and one
that is not upright (see Fig. 2).

Fig. 3. Sequence of postures imitated by subjects during accuracy confirmation
study.

This sequence of postures was explicitly developed to push the
limits of the Shimmer’s motion capture abilities and encompass
the full range of lower leg angles that would be seen in a weeklong study, from vertical to horizontal.
Both the VICON and Shimmer systems collected data at a
sample rate of 30 Hz. When comparing VICON angles to
Shimmer angles, root mean squared error (RMSE) calculations
showed that the two measurements differed by an average of
0.53 degrees for all three subjects. RMSE was 0.80 degrees for
subject 1, 0.13 for subject 2, and 0.66 for subject 3. Most error
occurred during the walking sequence from 30 to 40 seconds
(Fig. 4).

Fig. 2. The angle of each lower leg is compared to the critical angle (𝜃𝑐 ) to
determine uprightness.
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the NASA 10-minute Lean Test—meant to cause the onset of
PEM for subjects with ME/CFS, but have no effect on the control
group. Subjects were instructed to go about their lives in a
normal manner during the study.
III.

RESULTS AND DISCUSSION

A. Uptime Differences Between Disease Groups
Due to differences in activity levels brought on by the
presence and severity of ME/CFS, we expected the control group
to have the highest uptime and the severe ME/CFS group to have
the lowest uptime, with the moderate ME/CFS group’s uptime
somewhere in the middle. Group trends for weekly average
uptime scores supported this expectation.
Fig. 4. Comparison of angle data from VICON and Shimmers for one subject.

Uptime was calculated twice for each subject—once using
VICON angles and once using Shimmer angles. When reviewing
uptime scores for all three subjects, we found that the Shimmer
had an average error of 1.88% when compared to the VICON
system (Table 1).

Controls generally had average weekly uptimes above 30%.
Subjects with moderate ME/CFS generally had uptimes between
20 – 30%. Subjects with severe ME/CFS averaged daily uptime
scores below 20%. The non-overlapping group confidence
intervals (shown by the vertical colored lines in Fig. 5) are
evidence indicating that uptime differs by disease level.

TABLE 1. UPTIME DATA FOR BOTH THE VICON SYSTEM AND THE SHIMMER
Uptime (%)
System
VICON

Subject 1

Subject 2

Subject 3

29.61

31.47

24.79

Shimmer

29.74

30.67

25.45

Error

2.54%

0.42%

2.67%

This small amount of error was deemed negligible for our
application. Subject-to-subject differences in measurement
accuracy were also acceptably low.
C. Case-Control Study Design
For the planned case-control study, a total of 15 subjects
were outfitted with a Shimmer on each ankle. Each subject wore
both devices for six days—starting on a Monday and ending on
a Saturday. The 15 subjects were divided into three groups based
on disease level: (1) five subjects without ME/CFS (the
controls), (2) five subjects with moderate-level ME/CFS, and (3)
five subjects with severe-level ME/CFS. Due to limited Shimmer
availability, data collection was staggered so that one or two
subjects participated each week.

Fig. 5. Mean plot of uptime separated by disease level.

The results of an ANOVA test further substantiated these
group uptime differences, confirming that uptime differs
significantly between the groups (Table 2).
TABLE 2. RESULTS OF A MULTIPLE-FACTOR ANOVA

Factor

Degrees
of
Freedom

Sum of
Squares

Mean
Sum of
Squares

F value

P-value

Disease
Level

2

8570

4285

61.535

1.9e-15***

Day

5

505

101

1.450

0.219

Subject

12

2284

190

2.733

0.005**

Residuals

64

4317

70

-

-

The six-day data collection period was broken into two
phases. Phase one began on a Monday (when the subject traveled
to the BHC to be outfitted with the Shimmers) and ended 72
hours later—the following Thursday. Phase two began on
Thursday (where phase one ended) lasting another 72 hours
before ending on Sunday.
The data collected during phase one was meant to be a
baseline against which the data from phase two would be
compared; at the beginning of phase two, each subject performed

* Significance codes:

4

0 ‘***’

0.001 ‘**’

0.01 ‘*’

0.05 ‘.’

0.1 ‘ ’

The null hypothesis of this ANOVA test is that the mean
uptime is the same for all groups. A p-value of 1.9e-15 shows
that there is insufficient evidence to support the null hypothesis
(at the significance level 𝛼 = 0.05). As a result, we accept that
the alternative is true, indicating that there is a difference
between the mean group uptimes.
To further expand upon the result of this ANOVA, we used
Tukey’s HSD (honestly significant difference) test. Up to this
point, we have only shown that mean group uptimes are not all
equal. Tukey’s HSD test identified which specific group
differences exist. For all pairs of means, the calculated p-values
are far less than 𝛼 = 0.05, meaning that each group’s mean
uptime is different from all other groups (Table 3).
TABLE 3. TUKEY’S HSD TEST COMPARING UPTIME BY DISEASE GROUP
Disease
Level

Difference

Lower

Upper

P-value
(adjusted)

ModerateControl

-12.19

-18.17

-6.20

2.13e-05***

SevereControl

-25.54

-31.82

-19.25

0.00e+00***

SevereModerate

-13.35

-19.64

-7.06

9.80e-06***

0 ‘***’

0.001 ‘**’

* Significance codes:

0.01 ‘*’

0.05 ‘.’

These conclusions align with the observations of the BHC
and their understanding of ME/CFS. Symptoms of this disease—
such as post-exertional malaise (PEM) and orthostatic
intolerance (OI)—limit a patient’s ability to remain upright. As
disease severity increases, so do these physical limitations.
Therefore, we can objectively conclude that uptime corresponds
to the presence and severity of ME/CFS.
B. Uptime Before vs. After NASA Lean Test
Next, we looked for uptime differences before and after the
NASA Lean Test. The NASA 10-minute Lean Test requires
subjects to stand straight upright and lean against a wall, with
only the shoulder blades contacting the wall, and heels six inches
from the wall [14]. This test was expected to induce PostExertional Malaise (PEM) in subjects with ME/CFS, thereby
decreasing subsequent uptime scores.
In this comparison, a baseline uptime score was calculated
by averaging the three days before the NASA Lean Test:
Monday, Tuesday, and Wednesday. This baseline was used for
comparison when reviewing uptime scores for the proceeding
days: Thursday, Friday, and Saturday. Therefore, the variable
“Number of Days after Lean Test” has the following levels:

0.1 ‘ ’

With the combined results of the mean plot, ANOVA test,
and Tukey’s HSD test, we can confidently state that uptime
differs for all disease levels. Using the uptime scores collected
from all 15 subjects, we can define the uptimes expected for each
group. Controls (non-ME/CFS individuals) are expected to have
weekly uptime scores above 30%. Patients with moderate
ME/CFS are expected to have weekly uptime scores between
20% and 30%. Patients with severe ME/CFS are expected to
have weekly uptime scores below 20% (Fig. 6).

•

Baseline (average uptime for Monday, Tuesday, and
Wednesday)

•

1 Day after Lean Test (Thursday’s uptime)

•

2 Days after Lean Test (Friday’s uptime)

•

3 Days after Lean Test (Saturday’s uptime)

Despite our expectations, uptime averages for each group,
shown in Fig. 7, do not decrease following the Lean Test.
Instead, mean uptimes for ME/CFS groups spike one day after
the test.

Fig. 7. Group mean plots for uptime.

Fig. 6. Subject weekly average uptime scores (left) and corresponding scale of
expected uptime scores for each disease group (right).

Interestingly, the control group alone decreases after the
Lean Test; however, this change is due to weekend relaxation
rather than the effects of the NASA Lean Test. Furthermore, the
ME/CFS groups’ uptime spikes could have been a direct result
of participating in the NASA Lean Test. A 5-10% increase in
uptime equals roughly 1-2 hours of upright activity. This
increase could easily be the amount of time required to drive to
the BHC, take the Lean Test, and drive home.
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Because the confidence intervals in Fig. 7 overlap so
heavily, we don’t expect to find any significant difference in
mean uptimes before and after the NASA Lean Test. This
suspicion is confirmed by the high p-values shown in Table 4,
which indicate that there are no significant differences in uptime
by day.
TABLE 4. SINGLE-FACTOR ANOVA TABLES FOR EACH DISEASE
LEVEL
Degrees of Sum of
Freedom Squares

SEVERE

MODERATE

CONTROL

Factor

Mean Sum
of Squares

F value

3

630

210.0

1.658

0.218

Residuals

15

1900

126.6

-

-

Days After
Lean Test

3

58.8

19.59

0.431

0.734

Residuals

15

682.0

45.47

-

-

Days After
Lean Test

3

167.4

55.80

0.905

0.465

Residuals

15

801.5

61.65

-

-

0 ‘***’

0.001 ‘**’

0.01 ‘*’

Whatever the reason, it is indisputable that the NASA Lean
Test had no statistically significant effect on uptime. A better
experiment design would track each subject for a more extended
period before and especially after the NASA Lean Test, thus
establishing more accurate baseline uptime scores for each
subject. However, limitations in funding and time prohibited
these design improvements. Further investigation but may
provide deeper insight into the causes and effects of PEM.

P-value

Days After
Lean Test

* Significance codes:

more heavily following the NASA Lean Test to mitigate the
effects of PEM, thus unintentionally flattening uptime.

0.05 ‘.’

C. Comparison of HUA and Uptime
Finally, we turn to an evaluation of HUA as a proxy for
IMU-based uptime scores. Until this study, the only tool
researchers at the BHC had to evaluate daily upright activity was
HUA—a questionnaire that crudely captures the amount of time
an individual spends with the feet on the floor each day.
Historically, HUA was reported in units of hours; however, we
have converted HUA to a percentage of the day to accommodate
its comparison to IMU-based uptime measurements.
During our case-control study, subjects filled out daily HUA
questionnaires. The results of these surveys show that subjects
generally tend to overestimate uptime (Fig. 8).

0.1 ‘ ’

With the results of Table 4, we find ourselves forced to
reject the consensus that activity decreases after the NASA Lean
Test. This finding can be explained in a few different ways. For
one thing, our experimental design was not without flaws. On the
first day of each trial, the subject traveled to and from the BHC
to be equipped with the Shimmers. Due to the extreme sensitivity
of ME/CFS patients, this travel alone could have unintentionally
induced PEM. With patients experiencing PEM throughout the
entirety of the study (rather than just during days 4 through 6),
we would expect to see constant uptime scores. Future studies
should consider home-visits to reduce this effect.
The floor effect could be an alternative explanation for these
unexpected results; uptime can only go so low. Baseline uptimes
for the ME/CFS groups could already be at minimum allowable
levels. Further uptime reductions could mean a significant
decrease in lifestyle. (The quality of life for an individual with
ME/CFS is already very low). Some subjects in the moderate
ME/CFS group have part-time jobs; taking a few days off to
recover from PEM may not be an option. For the severe ME/CFS
group, it simply may not be possible to lower uptime from their
average four hours per day.

Fig. 8. HUA and uptime compared for the study’s combined ninety days of data.
Control subject data are included as indices 1-30, moderate ME/CFS data are
included as indices 31-60, and severe ME/CFS data are included as indices 6190. An index where uptime is not shown indicates a lack of Shimmer data.

Indeed, a correlation plot—broken up by disease level—
shows that HUA and uptime are not correlated for both ME/CFS
groups (Fig. 9).

Lastly, constant ME/CFS uptime scores could be a result of
self-medication. Except for the morning of the Lean Test,
ME/CFS subjects were permitted to take their prescribed
medication throughout the study. Subjects may have medicated
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treatments—a critical step towards receiving FDA-approval. The
BHC’s data shows that patients with severe ME/CFS are limited
to a bed or reclining chair for all but five hours each day;
increasing this number would be life-changing.
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